

Erratum

Correction to: T cell leukemia control via Ras-Raf pathway inhibition with peptides

Marin GH1, Rebollo A2, Bruzzoni-Giovanelli H3, Schinella G1, Piazzon I4, Duarte A4, Errecalde J1.

1 National University of La Plata - Pharmacology Department-CONICET

2 CIMI, Inserm/UPMC/CNRS- Université Pierre et Marie Curie, Paris 6, France; Centre d'Immunologie et des Maladies Infectieuses

3 Université Paris 7- Hôpital Saint Louis, Pharmacology - Centre d'Investigations Cliniques

4 National Academy of Medicine, Argentina, Experimental Immunology Laboratory

Received: 5 December 2017 Accepted: 5 December 2017

Abstract

In the original publication, the authors' names and their affiliations have been incorrectly typeset. The original article is now corrected.

Correction

In the original publication [1], the authors' names and their affiliations have been incorrectly typeset. The correct author list and affiliations should read as follows:

Marin GH1, Rebollo A2, Bruzzoni-Giovanelli H3, Schinella G1, Piazzon I4, Duarte A4, Errecalde J1.

1 National University of La Plata - Pharmacology Department-CONICET

2 CIMI, Inserm/UPMC/CNRS- Université Pierre et Marie Curie, Paris 6, France; Centre d'Immunologie et des Maladies Infectieuses

3 Université Paris 7- Hôpital Saint Louis, Pharmacology - Centre d'Investigations Cliniques

4 National Academy of Medicine, Argentina, Experimental Immunology Laboratory

We wish to apologise for any misunderstanding or inconvenience caused.

References

1. Marin GH, Rebollo A, Bruzzoni-Giovanelli H, Schinella G, Piazzon I, Duarte A, Errecalde J. T cell leukemia control via Ras-Raf pathway inhibition with peptides. *J Med Life*. 2017; 10(3):172-175.